Since 2015, Z Factor Limited has been at the forefront of pioneering therapeutic solutions to treat alpha-1-antitrypsin deficiency. Founded by Index Ventures in collaboration with the University of Cambridge, the company is focused on identifying and developing therapeutic agents for this condition. As a biotechnology company, Z Factor Limited operates in the cutting-edge intersection of science and medicine.
The last significant investment for Z Factor Limited was a £7.00M Series A investment received on 03 May 2017. This investment round saw contributions from Cambridge Innovation Capital, Medicxi, and University of Cambridge Enterprise. These renowned investors underline the credibility and potential of the company's mission and technology.
With the support of these stakeholders and its formidable expertise, Z Factor Limited is poised to continue making strides in addressing alpha-1-antitrypsin deficiency and potentially revolutionizing therapeutic solutions in the biotechnology industry.
